Back Talk

Back Talk: In a Jam? Do the Right Thing

Back Talk: In a Jam? Do the Right Thing

A textbook example of a firm doing the right thing in a crisis: J&J's decisive crisis management saved a brand

Who Will Pay the Piper?

Who Will Pay the Piper?

Robbing pharma to pay Senator Pothole will not encourage innovation

Back Talk: Eyes up, I'm talking to you!

Back Talk: Eyes up, I'm talking to you!

Your move? Lean in and make eye contact. Show that you care

Back Talk: Lonely at the top?

Back Talk: Lonely at the top?

Being in charge does not mean that you need to make every decision

Phone-free connections?

Phone-free connections?

At any well-run business meeting, a smartphone is not only disruptive but also signals that its user is less than fully engaged with the business at hand

Who's calling who "murky"?

Who's calling who "murky"?

Once we venerated doctors. Now we question every dollar they make

Give docs a shot in the arm

Give docs a shot in the arm

Is there anything that pharma can do to make doctors' lives easier?

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Pharma's role in cost control

Pharma's role in cost control

It may be time to adopt a model in which we help deliver healthcare

Think you own your brand? Think again

Think you own your brand? Think again

When you have a successful brand, you tamper with it at your peril


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.